Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2006

View Archived Issues

Snapshots on natural products in dermatology

NeuroMedix advances preclinical testing of Alzheimer's candidate Minozac

Advancis plans NDA filing for Amoxicillin PULSYS

Transition Therapeutics and JDRF partner on GLP1-I.N.T.

DDP-733 studies in phase Ib trial for GERD

FDA Advisory Committee votes against approval of Factive for ABS

ARRY-358: Novel MEK inhibitor effective in preclinical DHT

PC-DAC:Exendin-4 safe, with positive efficacy on glucose reduction in diabetics

Early efficacy trends demonstrated for RSD-1235 (oral) in atrial fibrillation

Two-year data show treatment effect of Campath in MS

Atu-027 RNAi shows efficacy in animal models of pancreatic cancer

Evotec discontinues EVT-301 development following liver function findings

Prometic reports progress on two key programs

Long-term pivotal study of Technosphere Insulin completes enrollment

GX15-070 enters phase II for cancer

Biogen Idec to develop, manufacture and commercialize aviptadil

TopoTarget to launch Savene in Europe ahead of schedule

HuMax-EGFr begins phase III trial in refractory head and neck cancer

Banyu and Teijin Pharma launch once-weekly alendronate products in Japan

Japanese launch for Temodal

Novel antiinfective agents disclosed in recent patent literature

Recent Pfizer and Ajinomoto patents describe new treatment strategies for cardiovascular diseases

Novel agents for anxiety, schizophrenia, etc., found in recent patents

BMS reports on novel dual angiotensin I and endothelin A receptor inhibitors

Novel dual KDR/FGFR inhibitors presented at the ACS meeting

Snapshots on novel hepatitis C virus polymerase inhibitors presented at the ACS meeting

Cytokinetics presents preclinical data on novel cardiac myosin activator CK-1316719

Nemod Biotherapeutics reports on a potent new antitumor-specific MUC1 antibody

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...